Head of the Headache Outpatient Department and Neurology Consultant
Charite Universitatsmedizin Berlin
Dr. Reuter’s research focuses on clinical and experimental studies on primary headache disorders primarily migraine. His basic science interests are the connection between the migraine aura and the headache as well as the signal transmission (on a molecular level) that results in the generation of headache. NO, COX and CGRP are the molecules of interest. His lab has experimental in vivo and in vitro models established to explore pain pathways in which these molecules are important.
Back to List
About Colucid
CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug
candidates with the potential to provide safe and effective treatments for CNS
disorders. The company's investors include Pappas Ventures, Domain Associates,
Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures.
Learn More About CoLucid
Lasmiditan
Lasmiditan is a member of a novel chemical class called "ditans."
Lasmiditan penetrates the central nervous system (CNS) and selectively
targets 5-HT1F receptors expressed in the trigeminal nerve
pathway.
Learn More About Lasmiditan